EGFR and non-small cell lung carcinoma: In the study by Zheng et al., EGFR C797S mutation, MET dysregulation, and TP53 plus RB1 co-occurrence were possible resistance mechanisms of LM in the progression of osimertinib of CSF in NSCLC [29].